Kanjinti

Trastuzumab, the active ingredient in Kanjinti, is a monoclonal antibody presented as an intravenous solution for intravenous use. It targets HER2‑positive cancers and is indicated for patients with metastatic breast cancer, early‑stage breast cancer in the adjuvant setting, and HER2‑positive gastric or gastro‑esophageal junction adenocarcinoma.

GNH USA supplies Kanjinti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for biologic products, ensuring product integrity from manufacturing to delivery.

Kanjinti is a HER2‑targeted monoclonal antibody used in the treatment of HER2‑positive cancers. - HER2‑positive metastatic breast cancer: improves overall survival and delays disease progression. - HER2‑positive early breast cancer (adjuvant setting): reduces risk of recurrence after surgery and standard therapy. - HER2‑positive gastric or gastro‑esophageal junction adenocarcinoma: enhances response rates and prolongs survival when combined with chemotherapy.

Kanjinti may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions (fever, chills, nausea, flushing) - Fatigue or weakness - Diarrhea or abdominal pain - Rash, pruritus or skin erythema - Nausea, vomiting or loss of appetite

Serious or Rare Side Effects: - Cardiac dysfunction, including reduced left ventricular ejection fraction - Severe hypersensitivity reactions, such as anaphylaxis or serum sickness - Thromboembolic events, including deep‑vein thrombosis or pulmonary embolism - Hepatotoxicity with elevated liver enzymes - Secondary malignancies (rare)

When using Kanjinti, several precautions should be observed to ensure patient safety and product integrity. - Cardiac assessment: evaluate baseline left ventricular ejection fraction and monitor periodically. - Infusion monitoring: administer under medical supervision and watch for signs of hypersensitivity. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; data are limited. - Concomitant cardiotoxic therapies: use caution when combined with anthracyclines or other agents affecting heart function. - Immunosuppression: monitor for infections and advise patients to report fever or chills promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kanjinti can interact with other medicines, and interactions are classified by clinical significance.

Major Interactions (Avoid): - Anthracyclines (e.g., doxorubicin): combined use increases risk of cardiac toxicity. - Live vaccines: may cause uncontrolled infection due to immune modulation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors or inducers: may alter clearance of concomitant drugs metabolized by this pathway. - Hormonal therapies (e.g., tamoxifen): potential for additive effects on cardiac function. - Anticoagulants: monitor coagulation parameters as trastuzumab may affect platelet function.